We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Livanova | LSE:LIVN | London | Ordinary Share | GB00BYMT0J19 | ORD GBP1.00 (DI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 50.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
The discussion is scheduled to begin at 11:00 a.m. Mountain Standard Time on Tuesday, November 8, 2016. It will be available to all interested parties through a live audiocast accessible via the investor relations section of LivaNova's website at www.livanova.com. Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the audiocast. A replay of the webcast will be available on the LivaNova website approximately 24 hours after the live presentation for 90 days after the event.
About LivaNovaLivaNova PLC is a global medical technology company formed by the merger of Sorin S.p.A, a leader in the treatment of cardiovascular diseases, and Cyberonics Inc., a medical device company with core expertise in neuromodulation. LivaNova transforms medical innovation into meaningful solutions for the benefit of patients, healthcare professionals, and healthcare systems.
The Company employs approximately 4,600 employees worldwide and is headquartered in London, U.K.
For more information, please visit www.livanova.com, or contact: Investor Relations and Media Karen King Vice President, Investor Relations & Corporate Communications Phone: +1 (281) 228-7262 Fax: +1 (281) 218-9332 e-mail: corporate.communications@livanova.com
1 Year Livanova Chart |
1 Month Livanova Chart |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions